Equity neuroscience最新文献

{"title":"Quality of death and end-of-life care among stroke patients: A comparative study of Mexican American and non-hispanic white surrogate decision makers.","authors":"Imadeddin Hijazi, Lewis B Morgenstern, Robert Michael Miller, Erin Case, Madeline Kwicklis, Darin B Zahuranec","doi":"10.1016/j.neuros.2025.100015","DOIUrl":"10.1016/j.neuros.2025.100015","url":null,"abstract":"<p><strong>Background: </strong>Racial and ethnic differences in patterns of end-of-life care have been previously reported, though there has been little work on the quality of end-of-life care in Mexican American (MA) stroke patients.</p><p><strong>Purpose: </strong>To compare surrogate decision maker reports of quality of death and end-of-life care among deceased MA and non-Hispanic White (NHW) stroke patients.</p><p><strong>Methods: </strong>Stroke patients and their surrogate decision makers were identified from an ongoing population-based cohort study in Nueces County, Texas, USA. Surrogates completed the Quality of End-of-Life Care (QEOLC, primary outcome) and the Quality of Death and Dying (QODD-1, secondary outcome) measures, both ranging 0-10 (10=better). Linear regression models with generalized estimating equations were used to assess ethnic differences in outcomes, adjusted for pre-specified covariates.</p><p><strong>Results: </strong>A total of 138 surrogates were enrolled for 113 deceased stroke patients (MA = 67, NHW = 46; median patient age 78 years; female: 53%; died in the hospital: 51%). Surrogates' median age was 60 years, and 75% were women. The overall QEOLC (Median=8.5; IQR 8,10) and QODD-1 scores (Median=10, IQR 8,10) were high. There was no ethnic difference on the QEOLC (0.03 ± 0.46, p = 0.95) or QODD-1 (-0.60 ± 0.54, p = 0.27) after adjustment.</p><p><strong>Conclusions: </strong>Surrogates in this community reported high quality of end-of-life care and death after stroke with no differences by ethnicity. The lack of disparity is a welcome finding, though more work in communities with lower acculturation and considering other aspects of end-of-life care is needed.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12700226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145759376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary prevention using a statin with or without aspirin among Ghanaian intracerebral hemorrhage survivors: A feasibility randomized trial.","authors":"Fred Stephen Sarfo, Hanson Ababio, Priscilla A Opare-Addo, Vida Obese, Manolo Agbenorku, Rexford Adu-Gyamfi, Sheila Adamu, John Akassi, Samuel Blay Nguah, Bruce Ovbiagele","doi":"10.1016/j.neuros.2025.100008","DOIUrl":"10.1016/j.neuros.2025.100008","url":null,"abstract":"<p><strong>Background: </strong>Intracerebral hemorrhage (ICH) survivors are at high risk for future ischemic vascular events and recurrent ICH. Due to an uncertain risk-benefit ratio, practice guidelines equivocate on whether antiplatelet therapies or statins should be prescribed for secondary prevention in the aftermath of a spontaneous ICH.</p><p><strong>Purpose: </strong>To preliminarily assess the tolerability and safety of low dose aspirin with or without atorvastatin at low and high doses for secondary prevention after ICH.</p><p><strong>Methods: </strong>In this single-center feasibility trial in Ghana, participants were randomized to 1 of 6 arms: no aspirin (ASA-0) + no atorvastatin (ATO-0) <i>n</i> = 10); aspirin 75 mg + no atorvastatin (ASA-75 + ATO-0, <i>n</i> = 10); no aspirin + atorvastatin 20 mg (ASA-0 + ATO-20, <i>n</i> = 10); no aspirin + atorvastatin 80 mg (ASA-0 + ATO-80, <i>n</i> = 10); aspirin 75 mg + atorvastatin 20 mg (ASA-75 + ATORVA-20, <i>n</i> = 11); and aspirin 75 mg + atorvastatin 80 mg (ASA-75 + ATORVA 80, <i>n</i> = 11) taken daily for 12 months. All participants received standard of care secondary prevention comprising of antihypertensive medications for blood pressure control. Outcomes assessed included major adverse cardiovascular events (stroke, myocardial infarction, vascular death), treatment-limiting side effects, change in Modified Rankin score and global cognition.</p><p><strong>Results: </strong>We enrolled 62 eligible recent ICH survivors between January 24, 2021, and March 16, 2022, mean (SD) age of 53 (11.6) years, 30 (48 %) were males. There were 3 deaths, one in each of these arms: ASA-0 + ATO-0; ASA-0 + ATO-20; ASA-0 + ATO-80. There was one non-fatal, ischemic stroke in the ASA-75 + ATO-80 arm and one non-fatal ICH in the ASA-75 + ATO-20 arm. No treatment limiting side effects were recorded.</p><p><strong>Conclusion: </strong>These feasibility and preliminary data suggest that aspirin with or without atorvastatin up to one year after a spontaneous ICH is well tolerated and may not raise recurrent ICH risk. A definitive large study with longer term follow-up is warranted.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12624418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145558900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of the visual analogue Parkinson's Disease Sleep Scale in Nigeria.","authors":"Olusegun Adediran, Olufisayo Elugbadebo, Hephzibah Oyedapo-Ishola, Aminat Kehinde Bakare, Akin Ojagbemi","doi":"10.1016/j.neuros.2025.100007","DOIUrl":"10.1016/j.neuros.2025.100007","url":null,"abstract":"<p><strong>Background: </strong>Sleep disturbances are common in persons with Idiopathic Parkinson's disease (PD) but often go undetected by attending physicians. Due to its simplicity, the visual analogue PD Sleep Scale (PDSS) could be valuable in the detection and management of sleep disturbances in contexts such as Nigeria where text heavy self-report assessments are difficult to implement due to limited formal education. We aim to test the utility of the PDSS in identifying nocturnal sleep problems in Nigerians with PD.</p><p><strong>Methods: </strong>We evaluated a dataset comprising information collected in southwestern Nigeria between February 2023 and June 2024 as part of a two-centre prevalence and case control study of behavioural symptoms in clinic attendees with PD. Controls were neurologically healthy persons who were matched for age, sex, education and outpatient status. Nocturnal sleep problems were assessed using the PDSS. We also independently administered the Neuropsychiatric Inventory Questionnaire (NPI-Q). We examined indicators of construct validity by comparing the PDSS with the NPI-Q nighttime behavioural subscale, known group validity by comparing with Hoehn and Yahrs stages of PD, and discriminant validity by comparing persons with PD with or without sleep problems. We generated Spearman correlation coefficients, Games-Howell post hoc adjustments in ANOVA, and step-down Bonferroni corrections for multiple comparisons.</p><p><strong>Results: </strong>Among 150 persons with PD and 150 matched neurologically healthy controls, PDSS scores were discriminated in 13 out of the 15 items (step-down Bonferroni corrected <i>p</i> < 0.003). Ten items demonstrated statistical correlations with the NPI-Q (<i>r</i> = 0.45 to 0.49 for overall sleep quality, sleep onset insomnia, sleep maintenance insomnia, and sleep related hallucinations). PDSS scores worsened as motor severity increased (Games-Howell post hoc adjusted <i>p</i> < 0.05 for Early to Severe PD).</p><p><strong>Conclusion: </strong>The PDSS was useful in identifying a variety of nocturnal sleep problems in people living with PD. These results provide support for the utility of the tool in Nigeria and similar contexts where many patients have limited or no formal education.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12657023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Locally adapting digital health technologies to address the global challenge of Parkinson's disease.","authors":"Karlo J Lizárraga, Isabel Camargo Salazar, Christine Zizzi, Stefano Romero, José Centeno Arispe, Alejandro Vela Quico, Timothy D Dye, E Ray Dorsey, Benjamín Castaneda","doi":"10.1016/j.neuros.2025.100010","DOIUrl":"10.1016/j.neuros.2025.100010","url":null,"abstract":"<p><p>Parkinson's disease is the fastest growing neurological disorder worldwide. As the global burden of the disease continues to grow, along with the environmental consequences of industrialization, it remains essential to diagnose, treat, and study Parkinson's disease among historically marginalized populations living in remote and relatively unindustrialized regions of the world. The diagnosis and monitoring of the motor manifestations of the disease depends on in-person examination of the speed, amplitude, and frequency of movement by trained providers. Digital health technologies allow synchronous, remote, video-based access to trained providers able to diagnose and monitor the progression of Parkinson's disease using clinical rating scales. Digital health technologies can be expensive, and their use requires sustainable access to trained providers, powerful computers and high-speed internet that are not widely available for historically marginalized populations, such as those living in remote Andean regions of Latin America. Local adaptation of health technologies could be promoted in partnership with historically marginalized communities to study their unique epidemiology while building local capacity to expand care and support community-driven education and research efforts.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12624569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145558911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"African stroke organization conference 2024: Strategies in reducing the burden of stroke.","authors":"Mehari Gebreyohanns, Deanna Saylor, Ezinne Onyinyechi Uvere, Osimhiarherhuo Adeleye, Uzma Hussain, Musisye Luchembe, Sidarrth Prasad, Raelle Tagge, Erica Danquah Asante, Rufus O Akinyemi, Fred Stephen Sarfo, DaiWai M Olson, Mayowa O Owolabi, Roger Bedimo","doi":"10.1016/j.neuros.2025.100006","DOIUrl":"10.1016/j.neuros.2025.100006","url":null,"abstract":"<p><p>The 4th annual African Stroke Organization Conference (ASOC) was held on November 4 and 5, 2024 at the University of Zambia School of Medicine in Lusaka, Zambia in a hybrid format. The location carried special significance as the University Teaching Hospital of Zambia had established its inaugural stroke unit in the country and showcased the early success in patient outcomes. This was the second hybrid format following the 2023 conference which was held in Ibadan, Nigeria after the first two conferences in 2021 and 2022 were held virtually because of the COVID19 pandemic. With the theme, <i>\"Controlling the Burden of Stroke: Gateway to Reducing the Burden of Non-Communicable Diseases (NCDs),\"</i> the conference emphasized the importance of an integrated approach to stroke prevention and management as a strategy to address NCDs. In its 4th year, ASOC has proved to be a very effective platform in highlighting stroke as a serious health burden in the African continent and a forum where current information is disseminated, solutions to problems are debated, and, most importantly, where the work of young African researchers is elevated. The hybrid format facilitated participation from 80 in-person attendees and 95 virtual participants, with full session recordings accessible to African Stroke Organization (ASO) members. Notable dignitaries included Zambia's Ministry of Health Permanent Secretary, Dr. Kennedy Lishimpi.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12219220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring deep brain stimulation willingness in Black individuals with Parkinson's disease.","authors":"Chiamaka Onuigbo, Chantale Branson","doi":"10.1016/j.neuros.2025.100012","DOIUrl":"10.1016/j.neuros.2025.100012","url":null,"abstract":"<p><strong>Background: </strong>Black individuals with Parkinson's disease (PD) receive deep brain stimulation (DBS) at significantly lower rates than non-White Hispanic individuals, a disparity associated with poorer outcomes.</p><p><strong>Methods: </strong>To explore potential patient-level factors contributing to decreased utilization, we conducted a cross-sectional pilot survey among 28 Black adults with PD who had not undergone DBS. Participants were recruited from neurology clinics in an urban safety-net hospital and local support groups in Atlanta. A structured survey was given to assess views towards DBS, including willingness to undergo DBS both currently and in a hypothetical scenario of worsening symptoms. Responses (YES, NO, MAYBE) were dichotomized (YES vs NO/MAYBE) for analysis. Thematic analysis explored participant perceptions.</p><p><strong>Results: </strong>The median age was 73.5 years. 50 % were male. When asked about current consideration of DBS, 8 (29 %) said YES, 14 % (50 %) said NO, and 6 (21 %) said MAYBE. In the hypothetical scenario, 19 (68 %) said YES, 4 (14 %) said NO, and 5 (18 %) said MAYBE. Notably, 12 participants shifted from NO/MAYBE to YES, while only one shifted in the opposite direction, indicating a significant increase in willingness under worsening conditions (X² = 7.692, p = 0.01). The most common reasons for hesitation were surgical concerns and lack of information.</p><p><strong>Conclusion: </strong>Findings suggest that rather than patient reluctance, reduced DBS uptake in this population may be more reflective of modifiable systemic barriers, such as limited awareness or disparities in the referral process. Educational outreach and equitable access to advanced therapies may address this gap.</p><p><strong>Clinical trial statement: </strong>This was a survey study and not a randomized clinical trial, so there is no clinical trial registration number.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145971667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex and gender differences in Lewy body dementia: a narrative review.","authors":"Ece Bayram","doi":"10.1016/j.neuros.2025.100009","DOIUrl":"10.1016/j.neuros.2025.100009","url":null,"abstract":"<p><p>Lewy body dementia (LBD), including Parkinson's disease dementia and dementia with Lewy bodies, is one of the most prevalent and burdensome type of dementias. Clinical diagnostic accuracy during life remains limited and there are currently only symptomatic therapy options without disease modification. However, recent advances in biomarkers and clinical trials are promising. Literature so far showed sex and gender differences in older adults without cognitive changes, people with all-cause dementia, Alzheimer's disease, and Parkinson's disease. While the number of studies in LBD are lower, understanding sex and gender differences and the underlying reasons can improve both diagnosis and treatment for LBD. Accordingly, the aim of this narrative review is to provide a summary of the literature for sex and gender differences in LBD. Majority of the studies for LBD investigating sex/gender differences so far focused on sex, with sex and gender terms being misused at times. Experiences of people in non-binary categories for sex or gender have yet to be investigated. While more research is needed, findings so far outline sex differences in prevalence, risk factors, biomarkers, symptoms, progression, treatment, daily life, and pathology for LBD. Sex-specific risk factors have also been reported, emphasizing the value of sex-stratified analyses and investigating female/male-specific factors such as sex hormones, menopause, and sex chromosomes. Lack of adequate research representation for females and women, as well as people from non-binary categories, is an important limitation that should be addressed to obtain more applicable findings in LBD.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12624417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145558893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Training Africans to Lead and Execute Neurological Trials and Studies (TALENTS): program overview and rationale.","authors":"Adewale E Ayodele, Iretioluwa M Bamtefa, IfeOluwa Owoseni, Erastus Amayo, Alfred Njamnshi, Adesola Ogunniyi, Paul Olowoyo, Rufus Akinyemi, Daniel Lackland, Mayowa Owolabi, Bruce Ovbiagele","doi":"10.1016/j.neuros.2025.100004","DOIUrl":"10.1016/j.neuros.2025.100004","url":null,"abstract":"<p><p>Africa bears a disproportionate burden of neurological diseases, yet clinical trials and research often lack representation from African populations, hindering the development of precision medicine for people of African ancestry. The Training Africans to Lead and Execute Neurological Trials and Studies (TALENTS) program, a Fogarty International Research Training D-43 initiative, aims to build sustainable neurological research capacity in Africa through a 5-year partnership between U.S. institutions, the University of Ibadan, and the African Academy of Neurology (AFAN). TALENTS recruits and trains 20 multidisciplinary African scholars post-doctoral researchers and clinicians in clinical neuroscience research, including trial design, multi-omics, and grant writing. Scholars complete an online Certificate in Clinical Research from the Medical University of South Carolina (MUSC), with four advancing to a Master's degree, preparing them as faculty for a new Master's in Neurological Research at the University of Ibadan. The program enhances mentorship and networking via AFAN meetings, peer mentoring, and monthly think tanks, fostering academic career development. Evaluation tracks scholars' academic positions, publications, and funding success. As of February 2025, 15 scholars across three cohorts have progressed, with notable career advancements, including faculty appointments and initiation of PhD study. TALENTS leverages Africa's diverse population and endemic neurological conditions to address global health disparities, aiming to produce a cadre of independent investigators contributing to neurological research and mentorship in Africa, with broader implications for African American health.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12249344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144629439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growing Data science Research in Africa to Stimulate Progress (GRASP) program: Rationale and overview.","authors":"Ezinne Uvere, Judit Kumuthini, Segun Fatumo, John Taiwo, Rufus Akinyemi, Adesola Ogunniyi, Godwin Ogbole, Benjamin Aribisala, Fred Sarfo, Ayodele Jegede, Joshua Akinyemi, Rajesh Vedanthan, Akinkunmi Okekunle, Daniel Lackland, Bruce Ovbiagele, Mayowa Owolabi","doi":"10.1016/j.neuros.2025.100003","DOIUrl":"10.1016/j.neuros.2025.100003","url":null,"abstract":"<p><p>Brain health is pivotal to achieving overall health and all current sustainable development goals (SDGs). However, a dedicated training program in brain health research to unravel its complex determinants, especially genetic, sociodemographic and lifestyle factors is lacking in Africa. The <b>G</b>rowing Data-science <b>R</b>esearch in <b>A</b>frica to <b>S</b>timulate <b>P</b>rogress (<b>GRASP</b>) is a three-year program designed to harness innovation potential to build sustainable data science (DS) research capacity among qualified African scholars through innovative partnerships and collaborations. This is aimed at promoting a learning environment for boosting knowledge, managing expectations, building support systems, and overcoming environmental barriers to create a sustainable system that will inspire innovative thinking for a remarkable transformation for producing Brain Health solutions for African and the world. Highlight of GRASP is its focus on improving the DS skills of selected scholars to explore sociodemographic determinants, dietary and lifestyle factors affecting brain health and cardiovascular risks, integrating sociodemographic data with cognitive, genomics, climate and geographical data. Ten African scholars from a cross-national/multidisciplinary postgraduate clinicians and researchers pool were selected during the 2024 cycle. Activities lined up during this program comprises of a nine-month Postgraduate Certificate program that includes six months virtual training activities, a compulsory 6-week residency at the University of Ibadan (UI), Nigeria (exclusive for five outstanding performing scholars), networking sessions at scientific meetings, annual mentor-mentee communication and research project. GRASP complements these attributes with the Master of Science in Clinical Research (MSCR) degree including competencies for the clinical and translational research workforce. GRASP scholars are assessed with periodic monitoring within three years after program completion based on academic positions and publications; funding for investigator-initiated research projects or career development awards. Building DS research capacity among African scholars via the GRASP program will re-orient current understanding and inspire creative solutions in Africa's approach to combating NCDs.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12249366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144629426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The society for equity neuroscience (SEQUINS): Seeking to eliminate global brain health inequities and disparities through research.","authors":"Bruce Ovbiagele","doi":"10.1016/j.neuros.2025.100001","DOIUrl":"10.1016/j.neuros.2025.100001","url":null,"abstract":"<p><p>Over 3 billion people are affected by a neurological condition, which is now the leading cause of illness and disability worldwide. However, burden of neurological disease is unevenly distributed, with certain groups and regions being more affected than others. Neurological disorders disproportionately affect certain racial and ethnic communities (e.g., Black, Indigenous, and people of color), those in lower socioeconomic groups, individuals living in underserved geographies including rural areas and low-income countries, and other marginalized populations. These populations tend to have poorer neurological outcomes because they are adversely impacted by the social drivers of brain health including lack of access to care, minimal participation in pivotal neurological trials, and underrepresentation in neuroscience research careers. Equity neuroscience is a multidisciplinary academic field devoted to understanding inequities in the manifestations of nervous system health, from particles to people, at multiple interacting levels, with a bidirectional local to global scope. The Society for Equity Neuroscience (SEQUINS) founded in 2024 aims to enhance brain health around the world by improving equitable nervous system care and outcomes through research. SEQUIINS seeks to be the central and unifying global organization for equity neuroscientists; supporting, teaching, promoting, and applying high quality research to achieve equitable nervous system care and health. This paper highlights the rationale for establishing a dedicated community of equity neuroscientists and presents the mission, vision, and emerging academic activities of SEQUINS.</p>","PeriodicalId":520832,"journal":{"name":"Equity neuroscience","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}